![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mid-States | LSE:MST | London | Ordinary Share | GB0002683034 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.625 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMST
RNS Number : 7599W
Mid-States PLC
25 November 2010
MID-STATES PLC (the "Company")
Development of the AD Miniature
The Company is pleased to announce that, as part of developing the commercial potential of its flagship Air Disinfection product, known as the 'AD', it has made good progress in developing a miniature 'AD' device specifically designed for the retail market. Development began on the AD miniature in January 2010 and the Company can now report that:
-- Independent laboratory results from the University of Wales Institute in Cardiff of the initial testing of the miniaturised air disinfection prototype are very positive and show the small device was equally as effective as the current AD device in reducing bacteria (Staphylococcus aureus - MRSA) in a test chamber with a volume of approximately 20 cubic metres (4.6 metres long x 2.2 meters high x 2.0 meters wide). Whilst further testing is required, this is a key stage in the development of the product and demonstrates the efficacy of the new device in a small room.
-- A patent covering the miniaturised air disinfection device has been applied for in the UK and, under the terms of the Paris Convention*, further applications can now be filed by the Company in all other major territories during the next twelve months.
Javier Segura, Managing Director of Mid-States PLC, commented: "We are delighted with the progress made with the development of the miniaturised device. We believe there are multiple environments to which the miniature AD is suited, for example the 'home health' market, which could be very significant. Along with continuing to further demonstrate the efficacy of the miniaturised device, we are actively looking for the right partner to assist us in addressing these large markets."
*Please note the Paris Convention is a treaty adhered to by about 130 countries, which helps those who wish to obtain patent protection in more than one country as this treaty allows patent applicants a period of 12 months from their first filing (in their home country) to file subsequent applications in other countries for the same invention.
For further information:
Mid-States PLC Tel: +44 (0) 20 7603 1515
Andrew Tonks, Finance Director
Panmure Gordon (UK) Limited Tel: +44 (0) 20 7459 3600
Andrew Godber
Cardew Group Tel: +44 (0) 20 7930 0777
Tim Robertson / Catherine Maitland
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBIBATMBTTBLM
1 Year Mid-states Chart |
1 Month Mid-states Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions